All AbMole products are for research use only, cannot be used for human consumption.
FCCP is a mitochondrial uncoupling agent and an oxidative phosphorylation (OXPHOS) inhibitor. FCCP is often used as an apoptosis inducer. FCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation. FCCP inhibits processing of wild-type APP. FCCP disrupts ATP synthesis by transporting hydrogen ions through a cell membrane before they can be used to provide the energy for oxidative phosphorylation. FCCP (5 μM or 500 nM), baf A1, and NH4Cl induce changes in Tf-Tx and Tf-F cellular fluorescence in K695 cells. FCCP (200 nM) protects and enhances the follicle integrity in cat ovarian tissue during short-term in vitro culture.
Cell Rep. 2023 Dec 1;42(12):113504.
Bisphenol S induces brown adipose tissue whitening and aggravates diet-induced obesity in an estrogen-dependent manner
FCCP purchased from AbMole
| Molecular Weight | 254.17 |
| Formula | C10H5F3N4O |
| CAS Number | 370-86-5 |
| Form | Solid |
| Solubility (25°C) | DMSO ≥ 90 mg/mL Ethanol ≥ 30 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Mitochondrial Related Products |
|---|
| VLX600
VLX600 is a novel inhibitor of iron-chelated oxidative phosphorylation (OXPHOS). VLX600 causes mitochondrial dysfunction and can show enhanced cytotoxicity in nutrient deficiency conditions. VLX600 showed selective cytotoxic activity against malignant cells and induced autophagy and had anticancer activity.*The compound is unstable in solutions, freshly prepared is recommended |
| Lixumistat
Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat (IM156) is a metformin derivative, which increases AMPK phosphorylation. |
| KL1333
KL1333 is an orally available, small organic molecule that reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. |
| Mito-TEMPO
Mito-TEMPO (MT) is a mitochondrial-targeted superoxide dismutase mimetic that protects the early stages of acetaminophen (APAP) hepatotoxicity by inhibiting the formation of peroxynitrite. Mito-TEMPO treatment inhibits APAP-induced EXPRESSION OF RIP3 kinase. |
| IMT1
IMT1 is the first, specific and non-competitive inhibitor of human mitochondrial RNA polymerase (POLRMT). IMT1 induces conformational changes in POLRMT that block substrate binding and transcription in a dose-dependent manner in vitro. IMT1 reduced deoxynucleoside triphosphate levels and citric acid cycle intermediates, resulting in significant depletion of cellular amino acid levels. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
